Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of your eye called the optic nerve. The symptoms can start so slowly that a patient may not notice them. The only way to find out if a person has glaucoma is to get a comprehensive dilated eye exam. Glaucoma may occur among people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for the increasing prevalence of glaucoma, which in turn is projected to drive the growth of the glaucoma therapeutics market in the near future.
The global glaucoma eye drops market is expected to witness significant growth during the forecast period owing to the increasing prevalence of glaucoma. For instance, according to the Centre for Disease Control and Prevention, in November 2020, an estimated 3 Mn people suffered from blindness due to glaucoma in the U.S. 2020.
- This report provides in-depth analysis of the global glaucoma eye drops market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period: 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global glaucoma eye drops market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Merck KGaA, Allergan plc ( A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.)
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics.
- The global glaucoma eye drops market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for glaucoma eye drops, research and consulting firms, new entrants, and financial analysts.
-
- Prostaglandin analogs
- Beta blockers
- Alpha agonists
- Carbonic Anhydrase Inhibitors (CAIs)
- Combined Medications
- Others (rho-kinase inhibitor, Cholinergic agonist)
-
- Angle-closure Glaucoma
- Open-angle Glaucoma
-
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
-
- Preservative Free
- BAK-Based
- Non BAK-Based Preservatives
-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- GCC
- Israel
- Rest of Middle East
- South Africa
- Central Africa
- North Africa
-
- Merck KGaA
- Allergan plc ( A subsidiary of AbbVie Inc)
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Bausch & Lomb
- Inotek
- Jadran-galenski laboratorij d.d. JGL d.d
- Aerie Pharmaceutical (A subsidiary of Alcon Management S. A)
- Mylan N.V. (A subsidiary of Viatris Inc.)
